CTRI/2013/12/004191已完成未知
Cumulative Irritancy Study (12 Days) - NI
Johnson Johnson0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male or female subjects 18 to 65 years of age of Indian Race.
- •-Subjects must be generally in good health as determined from a recent medical history which is on file with the investigator.
- •The ability of the subject to understand and sign a written informed consent form which must be obtained prior to treatment.
- •-Willingness to avoid the use of topical products at the test sites during the study.
- •-Willingness to avoid direct sun exposure to the test sites and the use of tanning beds for the duration of the study.
排除标准
- •-Individuals with active or history of psoriasis, active allergic skin responses, or active eczema as determined by the initial paperwork.
- •-Individuals with a history of eczema will be allowed on the study, as long as they complete a supplemental consent.
- •-Individuals with sunburn, acne, abrasions, scar tissue, or tattoos on the test sites, or diseases of the skin that might interfere with the evaluation made in this study or that expose study participants to unacceptable risks.
- •-Women known to be pregnant, nursing, or planning to become pregnant within the next six (6) months as determined by the initial paperwork.
- •-Use of topical steroids and/or drugs at test sites as determined by the initial paperwork.
- •-Current routine or frequent use of high doses of anti-inflammatory drugs for a defined medical condition as determined by the initial paperwork. Aspirin use should not exceed two tablets (650 mg) daily.
- •-Individuals who have had less than a two week rest period since completion of any previous patch testing.
- •-Individuals with uncontrolled metabolic diseases such as hypertension, hyperthyroidism, hypothyroidism, diabetes, etc.
- •-Individuals who have had a mastectomy in which axillary nodes were removed as determined by the initial paperwork.
- •-Individuals currently receiving any anticancer, immunosuppressive treatments/medications, and/or radiation as determined by the initial paperwork.
- •-Active or untreated skin cancer as determined by the initial paperwork.
- •Individuals with active hepatitis.
- •Previous clinically determined allergic reaction on a patch study, or known sensitivities or allergies to personal care products of any type.
- •-Individuals will be admitted to the study at the discretion of the Investigator based on medical history and findings of the pre-study interview and examination.
研究者
相似试验
已完成
不适用
Determination of irritation potential of the test products by the predictive patch test techniques.CTRI/2013/01/003285Johnson Johnson30
已完成
Unknown
Evaluation Of the Irritation and Sensitization Potential of Test Products in Healthy Adult Human SubjectsCTRI/2023/06/054569Himalaya Wellness Company201
已完成
不适用
Human Repeat Insult Patch Testing.CTRI/2020/06/025633Azafran Innovacion Limited208
已完成
不适用
Human Repeat Insult Patch TestingCTRI/2020/03/024322The Himalaya Drug Company240
进行中（未招募）
不适用
Assessment of Primary and Accumulated Irritation Potential, Skin Sensitization Potential and Skin Allergy and Toxicity Potential by Ultraviolet Light Accompanied by a Dermatologist for the Gel Cream ProductHypersensitivityN06.850.210RBR-74b44vfKosmosciense Ciência e Tecnologia Cosm Imp Exp Ltda